Humira's primary U.S. patents expired on October 16, 2023 [1][2]. This date marked the end of its market exclusivity for the originator, AbbVie [2].
What happens after Humira's patent expiry?
Following the expiration of key patents, biosimilar versions of Humira can now enter the U.S. market [1][2]. This is expected to increase competition and potentially lower drug costs [3].
What are Humira biosimilars?
Biosimilars are highly similar to existing biologic medicines, such as Humira, and have no clinically meaningful differences in terms of safety, purity, and effectiveness [4]. In the U.S., the Food and Drug Administration (FDA) approves biosimilars through a rigorous process [4]. Several biosimilar manufacturers have received FDA approval for their Humira biosimilars [5].
How do biosimilars compare to the original drug?
While biosimilars are designed to be highly similar to the reference product, they are not exact copies due to the complex manufacturing processes of biologic drugs [4]. However, these differences do not impact their clinical performance [4].
When did Humira's patent protection end in other regions?
Humira's patent protections in Europe expired earlier, starting in late 2018 [6]. This also allowed biosimilar versions to launch in European markets prior to the U.S. launch.
Who are the companies developing Humira biosimilars?
Multiple pharmaceutical companies have developed and launched biosimilars for Humira, including Amgen, Sandoz, Boehringer Ingelheim, and Coherus BioSciences, among others [5][7]. These companies are vying for market share in the post-patent landscape.
What is the impact of biosimilar competition on drug pricing?
The introduction of biosimilars typically leads to significant price reductions for the reference biologic drug [3]. This competition benefits patients and healthcare systems by making treatments more affordable [3].
What are the risks associated with biosimilar adoption?
While biosimilars offer significant benefits, concerns can sometimes arise regarding physician and patient confidence, interchangeability (whether a biosimilar can be substituted for the reference product without prescriber intervention), and market access [4][8].
Where can I find more information on drug patents and exclusivity?
For detailed information on drug patents, exclusivity periods, and biosimilar developments, resources like DrugPatentWatch.com provide comprehensive data and analysis [9].
Sources:
[1] https://drugpatentwatch.com/news/when-did-humira-go-off-patent
[2] https://www.drugpatentwatch.com/news/humira-patent-expiry-timeline
[3] https://www.drugpatentwatch.com/blog/biosimilar-uptake-and-price-erosion
[4] https://www.fda.gov/media/117777/download
[5] https://www.drugpatentwatch.com/drug/humira
[6] https://www.drugpatentwatch.com/drug/adalimumab/emea
[7] https://www.drugpatentwatch.com/biosimilars/adalimumab
[8] https://www.drugpatentwatch.com/blog/interchangeable-biosimilars-explained
[9] https://drugpatentwatch.com/